<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 22, 1996
--------------------------------
PHOENIX MEDICAL TECHNOLOGY, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-13401 31-0929195
- ---------------------------- ------------ -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
Route 521 West, P.O. Box 346, Andrews, South Carolina 29510
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (803) 221-5100
------------------------------
Not applicable
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Page 1
<PAGE> 2
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.
On March 22, 1996, the Registrant sold to Microtek Medical, Inc.
("Microtek") all of the Registrant's machinery, equipment and related tangible
property (including inventory and work-in-process) and all of its proprietary
information, and all other property and rights related to the Registrant's
manufacture and sale of adhesive skin drapes and scrub-and-prep products. The
purchase price, negotiated by the parties on an arms length basis, consisted of
$1,175,000 in cash and Microtek's undertaking to make contingent payments for
ten years of 11.5% of its sales of patented incise drapes and 3% of its sales
of other products in the Registrant's product line incorporating the patented
process, with a maximum of $1,825,000 on all contingent payments, a maximum
total purchase price of $3,000,000. Registrant's sales of items produced by
the assets sold to Microtek accounted for 4% of its total sales in 1995 and 5%
in 1994.
ITEM 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) Financial Statements of Businesses Acquired. Not applicable.
(b) Pro Forma Financial Information. Not applicable.
(c) Exhibits.
10.9 Asset Purchase Agreement dated as of March 22, 1996
between the Registrant and Microtek Medical, Inc.
Page 2
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.
PHOENIX MEDICAL TECHNOLOGY, INC.
By:/s/ Edward W. Gallaher, Sr.
------------------------------
Edward W. Gallaher, Sr.
President
Dated: April 3, 1996
Page 3
<PAGE> 4
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
EXHIBITS
FORM 8-K
CURRENT REPORT
Date of Report Commission File Number
March 22, 1996 0-13401
PHOENIX MEDICAL TECHNOLOGY, INC.
EXHIBIT INDEX
<TABLE>
<CAPTION>
Sequentially
Exhibit No Exhibit Description Numbered Page
- ---------- ------------------- -------------
<S> <C> <C>
10.9 Asset Purchase Agreement dated as of March 18,
1996 between the Registrant and
Microtek Medical, Inc.
</TABLE>
Page 4
<PAGE> 1
ASSET PURCHASE AGREEMENT
This Asset Purchase Agreement (this "Agreement") is made as of March
22, 1996, by and between Microtek Medical, Inc., a Delaware corporation
("Purchaser"), and Phoenix Medical Technology, Inc. a Delaware corporation (the
"Seller").
W I T N E S S E T H:
WHEREAS, the Seller is engaged in the business of adhesive skin drape
and scrub-and-prep products manufacturing (the "Business"); and
WHEREAS, Purchaser desires to purchase from the Seller, and the Seller
desires to sell to Purchaser, all of the assets used or useful in the operation
of the Business;
NOW, THEREFORE, in consideration of the premises and the mutual
covenants and agreements herein contained, the parties hereto agree as follows:
1. PURCHASE AND SALE OF ASSETS.
1.1. Purchase and Sale. At the Closing (as hereinafter defined)
and subject to the terms and conditions of this Agreement, Purchaser shall
purchase from the Seller, and the Seller shall sell to Purchaser, all of
Seller's right, title and interest in and to the following assets relating to
the Business that are owned by or under the control of the Seller, wherever
located, whether known or unknown, and whether or not on the books and records
of the Seller (collectively the "Purchased Assets"), free and clear of all
liens, security interests, claims and encumbrances, except for Assumed
Contracts (as hereinafter defined), and in each case excluding all other assets
used by the Seller (the "Excluded Assets"):
(a) All of Seller's equipment, machinery, spare parts,
tools, instruments, vehicles, furniture, fixtures and other similar
items of tangible personal property used in connection with the
Business and listed on the attached Schedule 1.1(a) (the "Tangible
Personal Property");
(b) All finished goods inventory of the Business, whether
on location, in transit or on consignment on the Closing Date (as
defined herein), including, without limitation, inventory located at
Sterilization Services of Georgia;
(c) All of Seller's raw materials inventory and
work-in-process relating to the Business;
(d) Such purchase orders, contracts and commitments of
the Seller relating to the Business and listed on the attached
Schedule 1.1(d);
(e) All of the Seller's (i) proprietary information,
trade secrets and confidential information, technical information and
data, trademarks, trade
<PAGE> 2
names and service marks related to the Business and the Purchased
Assets; (ii) machinery and equipment warranties and service contracts
related to the Purchased Assets; (iii) all causes of action not
pending as of the Closing Date related to or in connection with the
Purchased Assets; and (iv) all other documentation relating to the
operation of the Business, including all of Seller's transferable
right, title or interest in all licenses and permits necessary or
related to the operation of the Business; provided, that Seller's
right, title and interest in the corporate name "Phoenix Medical
Technology, Inc." is not part of the Purchased Assets; and
(f) Any books and records related to the Purchased
Assets, including all financial, accounting and property tax records,
computer data and programs, market data and records and all
correspondence with and documents pertaining to suppliers,
governmental authorities and other third parties (provided, however,
that copies of the same may be retained by the Seller).
1.2 Assumption of Liabilities. After the Closing, the Purchaser
shall assume and timely pay or satisfy, to the extent relating to periods on
and after the Closing, those specified contractual obligations listed as
"Assumed Contracts" on Schedule 1.2 hereto (collectively the "Assumed
Contracts"), as the same may be amended through the Closing Date with the
mutual consent of the Seller and Purchaser. Except as specifically set forth
above, Purchaser does not assume and shall in no event be liable for any debt,
obligation, responsibility or liability of the Seller, any subsidiary or any
affiliate or successor of the Seller, or any claim against any of the
foregoing, whether known or unknown, contingent or absolute, or otherwise.
1.3. Purchase Price.
(a) In consideration of the sale and transfer to
Purchaser by the Seller of the Purchased Assets, Purchaser hereby
agrees to pay the following aggregate consideration (collectively, the
"Purchase Price"):
(i) a fixed payment in an amount equal to One Million One
Hundred Seventy-five Thousand Dollars ($1,175,000), paid at
the Closing by the Purchaser to the Seller in cash or by
transfer of immediately available funds; and
(ii) a contingent payment made for a period of ten years,
whereby on a quarterly basis the Purchaser shall pay to the
Seller a dollar amount (the "Contingent Payment") equal to (A)
11.5% of the sales of patented incise drapes of the Business
sold by Purchaser during the ten-year period beginning on the
Closing Date (the "Payment Period") and (B) 3% of all sales of
other products in the Seller's product line incorporating the
patented process of the Business, which are listed on Schedule
1.3(a) hereto (including any modified version of such products
manufactured by the Seller as of the date hereof), that are
sold by Purchaser during the Payment Period. Each Contingent
Payment shall be paid to the Seller
2
<PAGE> 3
within 60 days of the end of each respective fiscal quarter
during the Payment Period. Amounts payable pursuant to this
Section 1.3(a)(ii) shall be determined after each such fiscal
quarter in accordance with generally accepted accounting
principles consistently applied ("GAAP") for such period.
Notwithstanding anything to the contrary herein, the aggregate
amount of the Contingent Payments made by the Purchaser shall
not exceed One Million Eight Hundred Twenty-five Thousand
Dollars ($1,825,000), subject to the downward adjustment
discussed under Section 1.3(b) hereof.
(b) The Seller hereby acknowledges that, for purposes of
calculating the Purchase Price, the Purchaser has relied upon the
Seller's representation that, except for the $3,000 monthly payments
due under Section 4(b) of the Agreement, no license fees or royalty
payments shall be required to be paid by the Purchaser with respect to
that certain Agreement dated October 15, 1987 (the "Microban
Agreement"), between the Seller and Microban Products Co.
("Microban"), or any other license agreements relating to Seller's
operation of the Business (together with the Microban Agreement, the
"License Agreements"), and the Seller hereby agrees that if the
Purchaser or any of its affiliates becomes liable for the payment of
any license fees or royalty payments due under the License Agreements,
then the Purchaser shall have the right to effect a dollar for dollar
reduction in the aggregate amount of the Contingent Payments and a
corresponding reduction in the Contingent Payment Ceiling, in each
case in an aggregate amount not to exceed the aggregate direct and
indirect costs and expenses incurred by the Parent and its affiliates
as a result of any such liability arising under the Microban
Agreement.
(c) The Purchase Price, including any Contingent
Payments, shall be allocated by Purchaser among the Purchased Assets
in accordance with Section 1060 of the Internal Revenue Code of 1986,
as amended; such allocation shall be based upon the recommendations of
KPMG Peat Marwick LLP and shall be subject to the mutual approval of
the Seller. Seller shall promptly notify Purchaser, and Purchaser
shall promptly notify Seller, of any adjustment that comes to its
attention that is proposed to be made by any federal, state or local
taxing authority with respect to the allocation of the Purchase Price.
2. CLOSING. A closing (the "Closing") to effect the purchase and sale of
the Purchased Assets shall be held at the offices of the Seller in Andrews,
South Carolina, on or before March 31, 1996, or at such other place or places
and/or on such other date as may be agreed upon by the parties (the "Closing
Date"). At the Closing, the Seller shall execute such bills of sale and
instruments of assignment as are necessary to convey title to the Purchased
Assets, and Purchaser shall pay to the Seller the cash portion of the Purchase
Price and execute and deliver to Seller such other documents and instruments as
shall be necessary to consummate the transactions contemplated by this
Agreement. All actions taken at the Closing shall be deemed to have been taken
simultaneously at the time the last of any such actions is taken or completed.
3
<PAGE> 4
3. REPRESENTATIONS AND WARRANTIES OF THE SELLER. Except as set forth on
the Seller Disclosure Schedule attached hereto as Schedule 3, the Seller hereby
represents and warrants to Purchaser as follows:
3.1. Organization and Good Standing of the Seller. The Seller is a
corporation duly formed and validly existing and in good standing under the
laws of the State of Delaware and, as of the Closing Date, is a foreign
corporation in good standing and operating with full corporate authority in the
State of South Carolina. The Seller has the corporate power and authority
necessary to own, lease and operate its properties and to carry on the
Business.
3.2. Corporate Power and Authority. The Seller has the corporate
power and authority and all licenses and permits required by governmental
authorities to execute, deliver and perform this Agreement.
3.3. Binding Effect. This Agreement and the other documents
contemplated hereunder (this Agreement and the other documents contemplated
hereunder referred to collectively as the "Transaction Documents") have been or
will have been duly authorized, executed and delivered by (to the extent
applicable) the Seller and are the legal, valid and binding obligation of the
Seller, enforceable in accordance with their respective terms, except that (i)
enforceability may be limited by bankruptcy, insolvency or other similar laws
affecting creditors' rights and (ii) the availability of equitable remedies may
be limited by equitable principles of general applicability.
3.4. Compliance with Other Instruments; Consents and Approvals.
Neither the execution and delivery by the Seller of the Transaction Documents
nor the consummation by it of the transactions contemplated thereby will at the
Closing Date violate, breach, be in conflict with, or constitute a default
under, or permit the termination or the acceleration of maturity of, or result
in the imposition of any lien, claim or encumbrance upon any Purchased Asset
pursuant to (i) the Seller's certificate of incorporation or bylaws, (ii) any
note, bond, indenture, mortgage, deed of trust, evidence of indebtedness, loan
or lease agreement, other instrument or any agreement to which the Seller is a
party, or to which the Purchased Assets are subject, or (iii) any law, rule,
regulation or licensing requirement applicable to, or any judgment, order,
injunction or decree binding on, the Seller, or to which the Purchased Assets
are subject. Except for those already obtained, no authorization, permit,
consent or approval is required to be obtained by the Seller to execute,
deliver or perform any of the Transaction Documents.
3.5. Compliance with Law. In respect of the Business, the Seller
is not in violation in any material respect of, and is not subject to any
governmental investigation under, any federal, state, local or foreign
statutes, ordinances, rules, regulations, orders or other laws. The Seller has
obtained and is in compliance with any permits required under any of the
foregoing laws or necessary to conduct the Business.
4
<PAGE> 5
3.6. Financial Statements and Records of the Seller.
(a) The Seller has delivered to Purchaser true, correct and
complete copies of income statements for both the "Skin Drape" and "Scrub &
Prep" product lines for the fiscal years ended December 31, 1993, 1994 and
1995, copies of which are attached on Schedule 3.6(a) hereto.
(b) Seller has made available to Purchaser (i) Seller's Annual
Reports on Form 10-K, including all exhibits filed thereto and items
incorporated therein by reference, (ii) Seller's Quarterly Reports on Form
10-Q, including all exhibits thereto and items incorporated therein by
reference, (iii) proxy statements relating to Seller's meetings of stockholders
and (iv) all other reports or registration statements (as amended or
supplemented prior to the date hereof), filed by Seller with the Securities and
Exchange Commission (the "SEC") since December 31, 1994, including all exhibits
thereto and items incorporated therein by reference (items (i) through (iv)
being referred to as the "Seller SEC Reports"). As of their respective dates,
the Seller SEC Reports did not contain any untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances under which they
were made, not misleading. Since December 31, 1994, Seller has filed all
material forms, reports and documents with the SEC required to be filed by it
pursuant to the federal securities laws and the SEC rules and regulations
thereunder, each of which complied as to form, at the time such form, report or
document was filed, in all material respects with the applicable requirements
of the Securities Act of 1933 and the Securities and Exchange Act of 1934 and
the applicable rules and regulations thereunder.
(c) The Purchased Assets have been recorded on the Seller SEC
Reports in accordance with GAAP; and the results of operations of the Seller
set forth in the Seller SEC Reports are correct and presented in accordance
with the accrual method of accounting applied on a consistent basis for the
periods presented.
3.7. Absence of Certain Changes. Since September 31, 1995, the
Seller has not (except as may result from the transactions contemplated by this
Agreement:
(i) suffered any change in the results of operations or
financial condition of the Business, other than changes in the
ordinary course of business that, individually or in the aggregate,
have not had a material adverse effect on the Business or the
Purchased Assets;
(ii) suffered any damage or destruction to or loss of a
Purchased Asset not covered by insurance, or any loss of suppliers,
that has a material adverse effect on the Business, results of
operations or financial condition of the Seller;
(iii) acquired or disposed of any Purchased Asset, or
incurred, assumed, guaranteed, endorsed, paid or discharged any
indebtedness, liability or obligation to be assumed by Purchaser
hereunder, or subjected or permitted
5
<PAGE> 6
to be subjected any material amount of the Purchased Assets to any
lien, claim, or encumbrance of any kind, except in the ordinary course
of business or pursuant to agreements in force at the date of this
Agreement;
(iv) forgiven, compromised, canceled, released, waived or
permitted to lapse any material rights or claims included as a part of
the Purchased Assets;
(v) except as permitted or provided by this Agreement,
entered into or terminated any material agreement, commitment or
transaction, or agreed or made any changes in material leases or
agreements, other than renewals or extensions thereof and leases,
agreements, transactions and commitments entered into in the ordinary
course of business; or
(vi) written up, written down or written off the book
value of any material amount of assets included in the Purchased
Assets.
3.8. No Material Undisclosed Liabilities; Certain Obligations of
the Seller. There are no material liabilities or obligations of the Seller
relating to the Business or the Purchased Assets, of any nature, whether
absolute, accrued, contingent or otherwise, other than (i) the liabilities and
obligations that are fully reflected, accrued or reserved against on the Seller
SEC Reports or incurred in the ordinary course of business and consistent with
past practices since September 31, 1995; or (ii) liabilities or obligations not
required to be disclosed in financial statements prepared in accordance with
generally accepted accounting principles; or (iii) liabilities and obligations
disclosed on Schedule III or elsewhere in this Agreement or other documents or
written information provided to Purchaser.
3.9. Tax Liabilities. The Seller has filed all federal, state,
county and local tax returns and reports required to be filed by it, including
those with respect to income, payroll, property, withholding, social security,
unemployment, franchise, excise and sales taxes, in each case to the extent
that the same relate to the Purchased Assets or the Business; has paid in full
all such taxes that have become due as reflected on any return or report and
any interest and penalties with respect thereto; and has made required cash
deposits with appropriate governmental authorities representing estimated
payments of taxes, including income taxes and employee withholding tax
obligations. No extension or waiver of any statute of limitations or time
within which to file any return has been granted to or requested by the Seller
with respect to any such tax. No unsatisfied deficiency, delinquency or
default for any tax, assessment or governmental charge has been assessed
against the Seller, nor has the Seller received notice of any such deficiency,
delinquency or default.
3.10. Title to Properties.
(a) The Seller has good and marketable title to the
Purchased Assets (other than leased assets), free and clear of any
lien, claim or encumbrance, except as reflected in the Seller
Disclosure Schedule and except for:
6
<PAGE> 7
(i) liens for taxes, assessments or other
governmental charges not yet due and payable or the validity
of which are being contested in good faith by appropriate
proceedings;
(ii) statutory liens incurred in the ordinary
course of business with respect to liabilities that are not
yet due and payable or the validity of which are being
contested in good faith by appropriate proceedings;
(iii) landlord liens contained in leases in the
ordinary course of business; and
(iv) such imperfections of title and/or
encumbrances as are not material in character, amount or
extent and do not materially detract from the value or
interfere with the use of the properties and assets subject
thereto or affected thereby.
(b) Upon the occurrence of the Closing, no stockholder of
Seller nor any affiliate of a stockholder will have any interest in or
will own any property or right used principally in the conduct of the
Business.
(c) Except for those assets acquired or disposed of since
September 31, 1995 in the ordinary course of business, all properties
and assets material to the present operations of the Business are
owned or leased by the Seller and are a part of the Purchased Assets.
3.11. Condition of Tangible Assets. The Tangible Personal Property
is, subject to ordinary wear and tear, in working order.
3.12. FDA Matters. No product of the Business requires, or will
require upon consummation of the transactions contemplated herein, any
approval, which has not previously been obtained, of the U.S. Food and Drug
Administration ("FDA") for the purpose for which it is being manufactured,
assembled or sold. Furthermore, the Seller has not made any changes or
modifications to its patented products or the labeling of its patented products
that would require a new 510(k) - Premarketing Notification under Section 21
CFR 807.81(a)(3). With respect to the Business, Seller has not received any
notice of any action or proceeding in the FDA including, but not limited to,
recall procedures, pending or, to the knowledge of the Seller, threatened
against Seller relating to the safety or efficacy of any of the Seller's
products.
3.13. Intellectual Property. The Seller Disclosure Schedule sets
forth a complete list of all copyrights, trademarks, service marks, patents and
similar intellectual property (collectively the "Intellectual Property") which
is used by the Seller in connection with the Business. The Seller is the
beneficial owner or authorized licensee of all such Intellectual Property and
does not infringe on the rights of any third party as a result of its use of
the Intellectual Property. No one has made, or to the knowledge of the Seller,
has threatened to make any claim that the
7
<PAGE> 8
operations of the Seller are in violation of or infringe upon any rights
relating to Intellectual Property or any other proprietary rights of any other
person or entity.
3.14. Litigation and Government Claims. There is no pending suit,
action or litigation, or administrative, arbitration or other proceeding or
governmental investigation or inquiry, to which the Seller is a party or to
which its assets are subject which would, if decided against the Seller,
individually or in the aggregate, have a material adverse effect on the
Business or the Purchased Assets. To the knowledge of the Seller, there are no
such proceedings threatened, contemplated, or any basis for any unasserted
claims (whether or not the potential claimant may be aware of the claim) which
would, if decided against the Seller, individually or in the aggregate, have a
material adverse effect on the results of operations of the Business or the
Purchased Assets.
3.15. Brokers and Finders. Except for the Seller's retention of
KPMG BayMark LLC (whose compensation shall be the sole responsibility of the
Seller), the Seller has not engaged any person to act or render services as a
broker, finder or similar capacity in connection with the transactions
contemplated herein and no person has, as a result of any agreement or action
by them, any right or valid claim against the Seller, Purchaser or any of
Purchaser's affiliates for any commission, fee or other compensation as a
broker or finder, or in any similar capacity in connection with the
transactions contemplated herein.
4. REPRESENTATIONS AND WARRANTIES OF PURCHASER. Purchaser hereby
represents and warrants to the Seller as follows:
4.1. Organization and Good Standing. Purchaser is a corporation
duly organized, validly existing and in good standing under the laws of the
State of Delaware.
4.2. Corporate Power and Authority. Purchaser has the corporate
power and authority and all licenses and permits required by governmental
authorities to execute, deliver and perform this Agreement.
4.3. Binding Effect. Each of the Transaction Documents has been or
will have been duly authorized, executed and delivered by Purchaser and is or
will be the legal, valid and binding obligation of it, enforceable in
accordance with its terms except that (i) enforceability may be limited by
bankruptcy, insolvency, or other similar laws affecting creditors' rights and
(ii) the availability of equitable remedies may be limited by equitable
principles of general applicability.
4.4. Compliance with Other Instruments; Consents and Approvals.
Neither the execution and delivery by Purchaser of the Transaction Documents
nor the consummation by it of the transactions contemplated thereby will
violate, breach, be in conflict with or constitute a default under, or permit
the termination or the acceleration of maturity of or result in the imposition
of any lien, claim or encumbrance upon any property or asset of Purchaser
pursuant to, its certificate of
8
<PAGE> 9
incorporation or bylaws, or any note, bond, indenture, mortgage, deed of trust,
evidence of indebtedness, loan or lease agreement, other agreement or
instrument, judgment, order, injunction or decree by which Purchaser is bound,
to which it is a party, or to which its assets are subject. Except for the
consent of its principal bank lender, no authorization, permit, consent or
approval is required to be obtained by Purchaser to execute, deliver or perform
any of the Transaction Documents.
4.5 SEC Reports. Purchaser has furnished to the Seller true and
complete copies of its Annual Report on Form 10-K for the most recent fiscal
year end, its proxy statement for its most recent annual meeting of
stockholders and its Quarterly Report on Form 10-Q for the three most recent
fiscal quarters. Purchaser will provide a copy of any other filings made with
the SEC when such filings are generally publicly available. Such documents did
not, on the date of filing in the case of such reports, or on the date of
mailing in the case of a proxy statement, contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading. Purchaser has filed all material
documents required to be filed by it with the SEC and all such documents
complied as to form with the applicable requirements of law. All financial
statements and schedules included in the documents referred to in this Section
4.5 were prepared in accordance with GAAP, except as noted therein, and fairly
present the information purported to be shown therein.
4.6. Brokers and Finders. Purchaser has not engaged any person to
act or render services as a broker, finder or similar capacity in connection
with the transactions contemplated herein and no person has, as a result of any
agreement or action by Purchaser any right or valid claim against the Seller,
Purchaser or any of the Seller's affiliates for any commission, fee or other
compensation as a broker or finder, or in any similar capacity in connection
with the transactions contemplated herein.
5. CERTAIN COVENANTS.
5.1. Cooperation. Each of the parties hereto shall, and shall
cause each of its affiliates to, use its best efforts to (i) obtain at the
earliest practicable date and, in any event, before the Closing Date, any
approvals, authorizations and consents necessary to consummate the transactions
contemplated by this Agreement; (ii) as reasonably requested by the other,
cooperate with and keep the other informed in connection with this Agreement;
and (iii) take such actions as the other parties may reasonably request to
consummate the transactions contemplated by this Agreement and diligently
attempt to satisfy, to the extent within its control, all conditions precedent
to its obligations to close the transactions contemplated by this Agreement;
provided, however, that nothing in this Section 5.1 shall require a party to
expend any monies except as otherwise specifically required under this
Agreement. Purchaser shall be responsible for all costs and expenses
associated with the crating, removal and transit (including insurance) of the
Assets and the risk of loss with respect to the Assets shall transfer as of the
Closing to Purchaser.
9
<PAGE> 10
5.2. Maintenance of Business and Purchased Assets. The Seller
covenants that between the date hereof and the Closing, except as contemplated
hereby or with the prior consent of Purchaser, it will refrain from doing any
of the following: (i) entering into any transaction with respect to the
Business other than in the ordinary course of business, (ii) permitting any
additional encumbrance, mortgage or pledge on any Purchased Asset or (iii)
disposing of any material Purchased Asset.
5.3. Access to Books and Records. Prior to the Closing Date and
upon reasonable notice, the Seller has and will give to the Purchaser and its
counsel, accountants and other authorized representatives, full access during
reasonable business hours to all of its properties, books, contracts, documents
and records and shall furnish to such persons all such information concerning
the affairs of the Business, including financial statements, as the Purchaser
may reasonably request in order that it may have full opportunity to make such
reasonable investigations as it shall desire for the purpose of verifying the
performance of and compliance with the representations, warranties, covenants
and the conditions contained herein or for other purposes reasonably related to
the transactions contemplated hereby. In the event that the Closing does not
occur and this Agreement is terminated, the Purchaser shall keep in confidence,
and shall cause its counsel, accountants and other representatives to keep in
confidence, and shall not use or disclose to others, all information provided
hereunder to it, except such information as is in the public domain.
5.4. Non-Competition Agreement. The Seller hereby covenants and
agrees that during the period commencing on the Closing Date and ending three
years after the Closing Date it will not, directly or indirectly, either as an
individual, a partner or a joint venturer, or in any other capacity, (i) invest
(other than investments in publicly owned companies which constitute not more
than 1% of the voting securities of any such company) or engage in any business
that is competitive with the Business, (ii) render services to a competitor of
the Business as a consultant, (iii) contact, solicit or attempt to solicit or
accept or direct business that is competitive with the Business, or (iv)
otherwise compete with the Business, except as provided in Section 5.5 of this
Agreement.
5.5. Post-Closing Sales from Purchaser to Seller. Seller and
Purchaser acknowledge that Seller will be obligated to fill certain purchase
orders for its products after the Closing, which are described on and/or
attached to the Seller Disclosure Schedule (the "Purchase Orders"). In order
to allow Seller to fulfill its obligations under the Purchase Orders, Purchaser
hereby agrees to sell the products to be delivered under such Purchase Orders
to Seller, on the same terms and conditions as Seller is obligated to sell such
products under the terms of the Purchase Orders; provided, that in no event
shall Purchaser have any obligation to make sales to Seller pursuant to this
Section 5.5 after September 1, 1996. Seller shall be responsible for the
shipment of such goods to the appropriate persons in the purchase orders.
5.6 Post-Closing Release of Liens. Seller hereby agrees to use
its best efforts to cause the liens held by The CIT Group/Credit Finance, Inc.
to be released as soon
10
<PAGE> 11
as possible after the Closing, but in no event later than the 10th business day
following the Closing Date. Seller further agrees to indemnify Purchaser
against any and all liabilities or obligations relating to such liens.
6. CONDITIONS PRECEDENT TO OBLIGATIONS OF THE SELLER. Except as may be
waived by Purchaser, the obligations of the Seller to consummate the
transactions contemplated by this Agreement shall be subject to the
satisfaction on or before the Closing Date of each of the following conditions:
6.1. Compliance. Purchaser shall have, or shall have caused to be,
satisfied or complied with and performed in all material respects, all terms,
covenants and conditions of this Agreement to be complied with or performed by
it on or before the Closing Date.
6.2. Representations and Warranties. All of the representations
and warranties made by Purchaser in this Agreement and in all certificates and
other documents delivered by Purchaser to the Seller pursuant hereto, shall
have been true and correct in all material respects as of the date hereof, and
shall be true and correct in all material respects at the Closing Date with the
same force and effect as if such representations and warranties had been made
at and as of the Closing Date, except for changes permitted or contemplated by
this Agreement.
6.3. Consents and Approvals. All third party consents and
approvals required to consummate the transactions contemplated by this
Agreement shall have been obtained and shall be in full force and effect.
7. CONDITIONS PRECEDENT TO OBLIGATIONS OF PURCHASER. Except as may be
waived by Purchaser, the obligations of Purchaser to consummate the
transactions contemplated by this Agreement shall be subject to the
satisfaction, on or before the Closing Date, of each of the following
conditions:
7.1. Compliance. The Seller shall have, or shall have caused to
be, satisfied or complied with and performed in all material respects all
terms, covenants, and conditions of this Agreement to be complied with or
performed by the Seller on or before the Closing Date.
7.2. Representations and Warranties. All of the representations
and warranties made by the Seller in this Agreement, the exhibits attached
hereto and in all certificates and other documents delivered by the Seller
pursuant hereto, shall have been true and correct in all material respects as
of the date hereof, and shall be true and correct in all material respects at
the Closing Date with the same force and effect as if such representations and
warranties had been made at and as of the Closing Date, except for changes
permitted or contemplated by this Agreement.
7.3. Consents and Approvals. All third party consents and
approvals required to consummate the transactions contemplated by this
Agreement, including the
11
<PAGE> 12
approval of the Purchaser's Board of Directors, shall have been obtained and
shall be in full force and effect.
7.4. Consulting Agreement. The Purchaser and Grover C. Mixon shall
have entered into the Consulting Agreement in substantially the form of Exhibit
A hereto.
7.5 Estoppel Certificate. The Purchaser shall have received a
certificate of Microban confirming the existence of the Microban Agreement, the
absence of any default thereunder, the consent of Microban to the transfer of
the Microban Agreement to the Purchaser and the discharge of the Seller (and
Purchaser) from the obligations set forth in the letter dated October 25, 1989.
7.6 Release of Lien. The Purchaser shall have received
documentation satisfactory to it evidencing the release of any and all liens
held against the Purchased Assets by The CIT Group/Credit Finance, Inc.
8. INDEMNIFICATION.
8.1. Indemnification of Purchaser. Subject to the limitations set
forth in Sections 8.3 and 8.4, the Seller shall indemnify and hold Purchaser
harmless from, against, for and in respect of (i) any and all damages, losses,
settlement payments, obligations, liabilities, claims, actions or causes of
action and encumbrances suffered, sustained, incurred or required to be paid by
Purchaser, net of any resulting income tax benefits to Purchaser, because of
the breach of any written representation, warranty, agreement or covenant of
the Seller contained in this Agreement which has not been expressly waived;
(ii) any and all liabilities of the Business in respect of periods prior to the
Closing Date which are not Assumed Contracts in accordance with the provisions
of this Agreement; and (iii) all reasonable costs and expenses (including,
without limitation, attorneys' fees, interest and penalties) incurred by
Purchaser in connection with any action, suit, proceeding, demand, assessment
or judgment incident to any of the matters indemnified against in this Section
8.1.
8.2. Indemnification of Seller. Subject to the limitations set
forth in Sections 8.3 and 8.4, Purchaser shall indemnify and hold the Seller
harmless from, against, for and in respect of: (i) any and all damages, losses,
settlement payments, obligations, liabilities, claims, actions or causes of
action and encumbrances suffered, sustained, incurred or required to be paid by
the Seller, net of any resulting income tax benefits to the Seller, because of
the breach of any written representation, warranty, agreement or covenant of
Purchaser contained in this Agreement which has not been expressly waived; (ii)
any and all debts, liabilities and obligations or which are Assumed Contracts
in accordance with the provisions of this Agreement; and (iii) all reasonable
costs and expenses (including, without limitation, attorneys' fees, interest
and penalties) incurred by the Seller in connection with any action, suit,
proceeding, demand, assessment or judgment incident to any of the matters
indemnified against in this Section 8.2.
12
<PAGE> 13
8.3. Survival of Representations, Warranties and Covenants. All
representations, warranties, covenants and agreements made by any party to this
Agreement or pursuant hereto shall be deemed to be material and to have been
relied upon by the parties hereto and shall remain operative and in full force
and effect following the Closing, and the warranties and representations
contained herein or in any certificate, exhibit or other document delivered in
connection herewith, shall survive for one year following the Closing Date.
Notice of any claim, whether made under the indemnification provisions hereof
or otherwise, based on a breach of a representation, warranty, covenant or
agreement must be given prior to the expiration of such representation,
warranty, covenant or agreement; and any claim not made within such period
shall be of no force or effect. The representations and warranties hereunder
shall not be affected or diminished by any investigation at any time by or on
behalf of the party for whose benefit such representations and warranties were
made. All statements contained herein or in any certificate, exhibit, list or
other document delivered pursuant hereto shall be deemed to be representations
and warranties made under this Agreement.
8.4. General Rules Regarding Indemnification. The obligations and
liabilities of each indemnifying party hereunder with respect to claims
resulting from the assertion of liability by the other party shall be subject
to the following terms and conditions:
(a) The indemnified party shall give prompt written
notice (which in no event shall exceed 30 days from the date on which
the indemnified party first became aware of such claim or assertion)
to the indemnifying party of any claim which might give rise to a
claim by the indemnified party against the indemnifying party based on
the indemnity agreements contained in Sections 8.1 or 8.2 hereof,
stating the nature and basis of said claims and the amounts thereof,
to the extent known;
(b) If any action, suit or proceeding is brought against
the indemnified party with respect to which the indemnifying party may
have liability under the indemnity agreements contained in Sections
8.1 or 8.2 hereof, the action, suit or proceeding shall, at the
election of the indemnifying party, be defended (including all
proceedings on appeal or for review which counsel for the indemnified
party shall deem appropriate) by the indemnifying party. The
indemnified party shall have the right to employ its own counsel in
any such case, but the fees and expenses of such counsel shall be at
the indemnified party's own expense unless the employment of such
counsel and the payment of such fees and expenses both shall have been
specifically authorized in writing by the indemnifying party in
connection with the defense of such action, suit or proceeding.
Notwithstanding the foregoing, (A) if there are defenses available to
the indemnified party which are inconsistent with those available to
the indemnifying party to such extent as to create a conflict of
interest between the indemnifying party and the indemnified party, the
indemnified party shall have the right to direct the defense of such
action, suit or proceeding insofar as it relates to such inconsistent
defenses, and the
13
<PAGE> 14
indemnifying party shall be responsible for the reasonable fees and
expenses of the indemnified party's counsel insofar as they relate to
such inconsistent defenses, and (B) if such action, suit or proceeding
involves or could have an effect on matters beyond the scope of the
indemnity agreements contained in Sections 8.1 and 8.2 hereof, the
indemnified party shall have the right to direct (at its own expense)
the defense of such action, suit or proceeding insofar as it relates
to such other matters. The indemnified party shall be kept fully
informed of such action, suit or proceeding at all stages thereof
whether or not it is represented by separate counsel.
(c) The indemnified party shall make available to the
indemnifying party and its attorneys and accountants all books and
records of the indemnified party relating to such proceedings or
litigation and the parties hereto agree to render to each other such
assistance as they may reasonably require of each other in order to
ensure the proper and adequate defense of any such action, suit or
proceeding. Whether or not the indemnifying party chooses to defend
or prosecute any claim involving a third party, all parties hereto
shall cooperate in the defense or prosecution thereof and shall
furnish such records, information and testimony and attend such
conferences, discovery proceedings, hearings, trials and appeals as
may be reasonably requested in connection therewith.
(d) The indemnified party shall not make any settlement
of any claims without the written consent of the indemnifying party.
9. MISCELLANEOUS.
9.1. Termination. This Agreement and the transactions contemplated
hereby may be terminated at any time on or before the Closing Date:
(i) by mutual consent of the Seller and Purchaser;
(ii) by Purchaser if there has been a material
misrepresentation or breach of warranty in the representations and
warranties of the Seller set forth herein or if there has been any
material failure on the part of the Seller to comply with its
obligations hereunder;
(iii) by the Seller if there has been a material
misrepresentation or breach of warranty in the representations and
warranties of Purchaser set forth herein or if there has been any
material failure on the part of Purchaser to comply with its
obligations hereunder;
(iv) by either of Purchaser or the Seller if the
transactions contemplated by this Agreement have not been consummated
by March 31, 1996; and
14
<PAGE> 15
(v) by either of the Seller or Purchaser if the
transactions contemplated hereby violate any order, decree, or
judgment of any court or governmental body or agency having competent
jurisdiction.
In the event of the termination of this Agreement pursuant to this Section 9.1,
this Agreement shall forthwith become null and void and of no further force or
effect; provided, however, that the parties hereto shall remain liable for any
breach of this Agreement prior to its termination pursuant to Section 9.1(ii)
or (iii); provided, further, that in the event of termination of this Agreement
due to a default or breach by a party hereto pursuant to Section 9.1(ii) or
(iii), the non-defaulting party shall be limited as to damages to the recovery
of reasonable fees, costs and expenses incurred and paid by the non-defaulting
party in connection with this transaction including any such expenses as may be
related to negotiations leading up to execution of this Agreement, and
including by way of illustration, accountants and attorney's fees, appraisals,
non-local travel and other out-of-pocket costs.
9.2. Expenses. Each of Purchaser and the Seller shall pay its own
expenses incurred in connection with this Agreement and the transactions
contemplated hereby.
9.3. Entire Agreement. This Agreement and the exhibits hereto
contain the complete agreement among the parties with respect to the
transactions contemplated hereby and supersede all prior agreements and
understandings, oral or written, among the parties with respect to such
transactions. Section and other headings are for reference purposes only and
shall not affect the interpretation or construction of this Agreement. The
parties hereto have not made any representation or warranty except as expressly
set forth in this Agreement or in any certificate or schedule delivered
pursuant hereto.
9.4. Public Announcements. Other than in connection with the
Seller's filing of its 10K-SB, no party to this Agreement shall issue any press
release relating to, or otherwise publicly disclose, the transactions
contemplated by this Agreement without the prior approval of the other parties.
Notwithstanding the foregoing, any party may make such disclosure as may be
required by law, provided the disclosing party obtains from the other party
prior approval of the substance of the proposed disclosure (such as the content
of a proposed press release), which approval may not be unreasonably withheld
or delayed.
9.5. Counterparts. This Agreement may be executed in any number of
counterparts, each of which when so executed and delivered shall be deemed an
original, and such counterparts together shall constitute only one original.
9.6. Notices. All notices, demands, requests or other
communications that may be or are required to be given, served or sent by any
party to any other party pursuant to this Agreement shall be in writing and
shall be mailed by first-class,
15
<PAGE> 16
registered or certified mail, return receipt requested, postage prepaid, or
transmitted by a reputable overnight courier service or by hand delivery,
addressed as follows:
(i) If to the Seller:
Phoenix Medical Technology, Inc.
Route 521 West
P.O. Box 346
Andrews, South Carolina 29510
Attention: Edward W. Gallaher, Sr.,
President and CEO
(ii) If to the Purchaser:
Microtek Medical, Inc.
512 Lehmberg Road
P.O. Box 2487
Columbus, Mississippi 39704
Attention: Kimber L. Vought, President
and CEO
Each party may designate by notice in writing a new address to which any
notice, demand, request or communication may thereafter be so given, served, or
sent. Each notice, demand, request or communication that is mailed, delivered,
or transmitted in the manner described above shall be deemed sufficiently
given, served, sent and received for all purposes at such time as it is
delivered to the addressee (with the return receipt, the delivery receipt or
the affidavit of courier or messenger being deemed conclusive evidence of such
delivery) or at such time as delivery is refused by the addressee upon
presentation.
9.7. Assignment; Successors and Assigns. This Agreement may not
be assigned by either of the parties hereto without the written consent of all
the other parties; provided, however, that the Purchaser shall be entitled to
assign this Agreement to any subsidiary corporation so long as the Purchaser
remains liable for the obligations of Purchaser hereunder and under the other
Transaction Documents. This Agreement and the rights, interests and
obligations hereunder shall be binding upon and shall inure to the benefit of
the parties hereto and their respective heirs, executors, administrators,
successors and assigns.
9.8. Governing Law. This Agreement shall be construed and
enforced in accordance with the laws of the State of Texas.
9.9. Waiver and Other Action. This Agreement may be amended,
modified or supplemented only by a written instrument executed by the parties
against which enforcement of the amendment, modification or supplement is
sought.
9.10. Severability. If any provision of this Agreement is held
to be illegal, invalid or unenforceable, such provision shall be fully
severable, and this Agreement shall be construed and enforced as if such
illegal, invalid or unenforceable provision
16
<PAGE> 17
were never a part hereof; the remaining provisions hereof shall remain in full
force and effect and shall not be affected by the illegal, invalid or
unenforceable provision or by its severance; and in lieu of such illegal,
invalid or unenforceable provision, there shall be added automatically as part
of this Agreement, a provision as similar in its terms to such illegal, invalid
or unenforceable provision as may be possible and be legal, valid and
enforceable.
9.11. Third-Party Beneficiaries. This Agreement and the rights,
obligations, duties and benefits hereunder are intended for the parties hereto,
and no other person or entity shall have any rights, obligations, duties and
benefits pursuant hereto.
17
<PAGE> 18
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year first above written.
MICROTEK MEDICAL, INC.
By:
-----------------------------------
Kimber L. Vought, President
PHOENIX MEDICAL TECHNOLOGY, INC.
By:
-----------------------------------
Edward W. Gallaher, Sr., President
18
